*; Wolfram Doehner, MD*†; Mathias Rauchhaus, MD*; Mariantonietta Cicoira, MD*‡; Darrel P. Francis, MD*; Andrew J.S. Coats, DM*; Andrew L. Clark, MD§; Stefan D. Anker, MD, PhD*†">
Journal Home
Search for

Volume 9, Issue 1, Pages 29-35 (February 2003)


View previous. 5 of 11 View next.

Body mass and survival in patients with chronic heart failure without cachexia: The importance of obesity

Constantinos H. Davos, MD, PhD*, Wolfram Doehner, MD*†, Mathias Rauchhaus, MD*, Mariantonietta Cicoira, MD*‡, Darrel P. Francis, MD*, Andrew J.S. Coats, DM*, Andrew L. Clark, MD§, Stefan D. Anker, MD, PhD*†

Received 10 September 2002; received in revised form 25 November 2002 and 27 November 2002

Abstract 

Background: Cachexia in chronic heart failure carries a poor prognosis, but little is known about the influence of body mass on the prognosis of noncachectic heart failure patients. Methods: We studied 589 consecutive chronic heart failure patients followed for at least a year, in whom there were accurate baseline data for body mass. Results: Average age was 64.5 ± 12.4 years, left ventricular ejection fraction (LVEF) 30.9 ± 0.73%. Cachexia was present in 64. Noncachectic patients were divided into quintiles of body mass index (BMI), Q1 (BMI 22.2 ± 1.5) to Q5 (BMI 34.1 ± 2.8). There was no difference among the 5 groups in age, exercise capacity or LVEF. Survival was greatest in Q4 (1-year survival [95% confidence interval (CI)]) 0.91 (0.85–0.96) and 3-year survival 0.81 (0.73–0.89). Relative risks compared with Q4 were Q1: 2.3 (1.4–3.8); Q2: 1.7 (1.1–2.9); Q3: 1.8 (1.1–3.0); and Q5: 1.5 (0.9–2.5). In multivariate analysis of 1 year follow-up, peak oxygen consumption (hazard ratio with 95% CI) (0.89 [0.82–0.97]; P = .006), LVEF (0.94 [0.91–0.97]; P = .0002) and BMI (0.90 [0.82–0.98]; P = .02) independently predicted 1-year survival with a combined X2 value of 42.4. Age (1.01 [0.98–1.05] and diagnosis (1.56 [0.78–3.11]) was not a predictor of survival. Conclusion: In patients with chronic heart failure, increasing BMI is not an adverse prognostic feature. Thinner patients appear to have a poorer prognosis.

London, United Kingdom

Berlin, Germany

Verona, Italy

East Yorkshire, United Kingdom

From the *Department of Cardiac Medicine, National Heart & Lung Institute, London, United Kingdom; Franz-Volhard-Klinik (Charité, Campus Berlin-Buch), Max-Delbrück-Centrum, Berlin, Germany; Divisione Clinicizzata di Cardiologia, Universita' Degli Studi di Verona, Verona, Italy; and §Department of Academic Cardiology, Castle Hill Hospital, Cottingham Hull, East Yorkshire, United Kingdom

 Reprint requests: Dr. A. L. Clark, Department of Academic Cardiology, Castle Hill Hospital, Castle Road, Cottingham Hull HU16 5JQ, East Yorkshire, UK.

PII: S1071-9164(02)25404-4

doi:10.1054/jcaf.2003.4


View previous. 5 of 11 View next.